NCT04041648View on ClinicalTrials.gov

Single Ascending Dose Study for Evaluation of Safety, Tolerability and Pharmacokinetics of L606

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

November 9, 2018

Primary Completion Date

September 20, 2019

Study Completion Date

May 12, 2020

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

L606 (Liposomal Treprostinil) Inhalation Solution 51ug

Single ascending dose

DEVICE

L606 Inhalation System

Single ascending dose

OTHER

Placebo Solution

Single ascending dose

Trial Locations (1)

78744

PPD, Austin

Sponsors

Collaborators (1)

PPD Development, LP
All Listed Sponsors
collaborator

PPD Development, LP

INDUSTRY

lead

Pharmosa Biopharm Inc.

INDUSTRY